Clinical trials: Disease, Hodgkin
Mantle-Cell Lymphoma
A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
Patients with mantle cell lymphoma (MCL) that has relapsed (come back) or refractory (progressed on treatment) will receive ixazomib and ibrutinib.
- Trial name
- PrE0404 (NCT03323151)
- Testing
- Ixazomib, Ibrutinib
- Where
- 14 sites in United States
- Volunteers
- 43 people
- Sponsor
- PrECOG, LLC.
Non-Hodgkin's Lymphoma
A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
This is a Phase 1, open-label, multicenter study evaluating the safety, pharmacokinetic profile, and preliminary efficacy of ABT-199 in combination with Bendamustine/Rituximab in approximately 60 subjects with relapsed or…
- Trial name
- NCT01594229
- Testing
- ABT-199, Rituximab, Bendamustine
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- AbbVie
Mantle Cell Lymphoma
A Study of OLR in First-line Treatment of Mantle Cell Lymphoma
This is a single-arm, multicenter, open label phase II clinical study to evaluate the efficacy and safety of OLR in the treatment of initially treated mantle cell lymphoma.
- Trial name
- NCT05076097
- Testing
- Orelabrutinib in in combination of rituximab and lenalidomide(OLR)
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Diffuse Large B Cell Lymphoma
The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk
The Safety and Effectiveness of Four Courses of R-CHOP Plus Four Courses of Rituximab Versus Six Courses of R-CHOP Plus Two Courses of Rituximab in the Treatment of Naive, Low-risk, Non-mass Diffuse Large B-cell Lymphoma: a…
- Trial name
- NCT05018520
- Testing
- Six Courses of R-CHOP Plus Two Courses of Rituximab, Four Courses of R-CHOP Plus Four Courses of Rituximab
- Where
- China
- Volunteers
- 640 people
- Sponsor
- Ruijin Hospital
Lymphoma, T-Cell, Cutaneous
CTCL Directed Therapy
Cutaneous lymphomas are rare cancers of lymphocytes (white blood cells) that involve the skin. Mycosis Fungoides (MF) is the most common type of Cutaneous T-cell lymphoma (CTCL) that typically presents with red, scaly patches…
- Trial name
- NCT03116659
- Testing
- Doxycycline, Imiquimod
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- James J. Peters Veterans Affairs Medical Center
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Real-World Study of Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
B-cell non-Hodgkin lymphoma (B-NHL) is the most common type of lymphoma. Although first-line R-CHOP can cure a proportion of patients, approximately 30%-40% relapse or become refractory (R/R).
- Trial name
- NCT07695896
- Testing
- Glofitamab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Yanyan Liu
Newly Diagnosed Peripheral T-cell Lymphoma
Treatment of Newly Diagnosed Peripheral T-cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of Apatinib Combined With CHOP Regimen(cyclophosphamide, vincristine, epirubicin, prednisone in the treatment of newly diagnosed peripheral T-cell lymphoma.
- Trial name
- NCT03631862
- Testing
- Apatinib, CHOP Regimen
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhengzhou University
Dementia, Mild
Trial-based Effectiveness and Cost-effectiveness of the Partner in Balance Intervention
Rationale: Informal care is one of the most important sources of care for dependent elderly people. The Partner in Balance (PIB) intervention aims to prepare and support informal caregivers for their caregiving tasks.
- Trial name
- NCT05450146
- Testing
- Partner in Balance
- Where
- Netherlands
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- Maastricht University
COPD Exacerbation
High Flow Nasal Cannula vs NPPV in Moderate Chronic Obstructive Pulmonary Disease Exacerbation
For moderate AECOPD(pH<7.35), several guidelines have strongly recommended NPPV as standard therapy, which can reduce the rate of intubation and mortality.
- Trial name
- NCT03014869
- Testing
- High flow nasal cannula
- Where
- China
- Volunteers
- 351 people
- Sponsor
- China-Japan Friendship Hospital
Cognitive Impairment
Health Care Courses of Elderly Hospitalized Patients for Inappropriate Reasons: Qualitative and Economic Analyzes
For almost 17 % of cases patients over 75 years are sent for inappropriate reasons to the emergency unit. They are described as inappropriate hospitalization because they don't require the use of technical platform or diagnostic…
- Trial name
- PAGE (NCT02749669)
- Testing
- Qualitative research
- Where
- France
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Régis AUBRY
Hepatic Impairment
A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693
Subcutaneous administration of AZD2693 single dose in participants with hepatic impairment
- Trial name
- NCT05919069
- Testing
- AZD2693
- Where
- 3 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Lymphoma, Follicular
A Study of Rituximab in Combination With Chemotherapy in Relapsed/Refractory Follicular Lymphoma
This is a Phase 4, open, prospective, non-interventional, multicenter trial for previously treated adult participants with relapsed/refractory follicular lymphoma (FL).
- Trial name
- REFLECT 2 (NCT02472756)
- Testing
- Chemotherapy, Rituximab
- Where
- 6 sites in Serbia
- Volunteers
- 41 people
- Sponsor
- Hoffmann-La Roche
Acute Myeloid Leukemia, Myelodysplasia
Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies
This is a pilot study designed to evaluate the safety and feasibility of performing umbilical cord blood transplants in adults with high-risk hematopoietic malignancies. A novel myeloablative preparative regimen will be used.
- Conditions
- Acute Myeloid Leukemia, Myelodysplasia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT00514722
- Testing
- umbilical cord stem cells
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of California, San Francisco
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Current protocols use G-CSF to mobilize hematopoietic progenitor cells from matched sibling and volunteer unrelated donors. Unfortunately, this process requires four to six days of G-CSF injection and can be associated with side…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma
- Trial name
- NCT02639559
- Testing
- BL-8040, Leukapheresis, Hematopoietic cell transplant
- Where
- 3 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
MCL, Mantle Cell Lymphoma
Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma
This is a phase II trial, with the aim of developing a chemotherapy-free regimen for untreated patients with mantle cell lymphoma (MCL).
- Trial name
- ALTAMIRA (NCT05214183)
- Testing
- Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma
- Where
- 20 sites in Denmark, Finland and 3 more
- Volunteers
- 81 people
- Sponsor
- Nordic Lymphoma Group
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The EAP is for patients with relapsed/refractory diffuse large b-cell lymphoma (R/R DLBCL) that cannot be treated by currently available drugs, cell therapy, or clinical trials.
- Trial name
- NCT04705454
- Testing
- Loncastuximab Tesirine
- Sponsor
- ADC Therapeutics S.A.
Head and Neck Cancer, Cervical Cancer
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
This is a multicenter, open-label, phase Ib/IIa study. The first part of the study will evaluate the safety, tolerability and preliminary efficacy of ILB2109 and Toripalimab in patients with locally advanced or metastatic solid…
- Conditions
- Head and Neck Cancer, Cervical Cancer, Endometrial Cancer, Triple Negative Breast Cancer
- Trial name
- NCT05955105
- Testing
- ILB-2109, Toripalimab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Innolake Biopharm
B-Cell Lymphoma, Unspecified, Grade 1 Follicular Lymphoma
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This phase I study studies the side effects and best dose of venetoclax and lenalidomide when given together with obinutuzumab in treating patients with B-cell non-Hodgkin lymphoma that has returned after a period of improvement…
- Conditions
- B-Cell Lymphoma, Unspecified, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
- Trial name
- NCT02992522
- Testing
- Lenalidomide, Obinutuzumab, Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Beth Christian
Diffuse Large B-Cell Lymphoma
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
The purpose of this study is to learn about the effects of three study medicines [maplirpacept (PF-07901801), tafasitamab, and lenalidomide] when given together for the treatment of diffuse large B-cell lymphoma (DLBCL) that: is…
- Trial name
- NCT05626322
- Testing
- Maplirpacept, Tafasitamab, Lenalidomide
- Where
- 7 sites in United States, Japan and 1 more
- Volunteers
- 6 people
- Sponsor
- Pfizer
Relapsed or Refractory Follicular Lymphoma
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
The purpose of this study is to evaluate the efficacy and safety of Liso-cel compared to standard of care in adults with Relapsed or Refractory Follicular Lymphoma.
- Trial name
- NCT06313996
- Testing
- Cyclophosphamide, Doxorubicin, Vincristine
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.